Major Strides in HER2 Blockade for Metastatic Breast Cancer P Sharma, NEJM, February 12, 2020

Hot Topics of the Day|PHGKB


Last Posted: Feb 13, 2020

---

• Major Strides in HER2 Blockade for Metastatic Breast Cancer
  P Sharma, NEJM, February 12, 2020
• Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
  S Modi et al, NEJM, February 12, 2020
• Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer.
  Kurian Allison W et al. JAMA oncology 2020 Feb e196400
• Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG).
  Kittaneh Muaiad et al. Clinical breast cancer 2020 Jan
• Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
  Soenderstrup I M H et al. Acta oncologica (Stockholm, Sweden) 2018 Jan 57(1) 95-101
• Detection of Germline Mutations in Breast Cancer Patients with Clinical Features of Hereditary Cancer Syndrome Using a Multi-Gene Panel Test.
  Shin Hee-Chul et al. Cancer research and treatment : official journal of Korean Cancer Association 2020 Feb
• Experiences of BRCA1/2 Gene Mutation-Positive Women With Cancer in Communicating Genetic Risk to Their Relatives.
  Seven Memnun et al. Cancer nursing 2020 Jan
• Factors that impact risk management decisions among women with pathogenic variants in moderate penetrance genes associated with hereditary breast cancer.
  Napoli Melissa et al. Journal of genetic counseling 2020 Feb
• Gail Model Underestimates Breast Cancer Risk in Thai Population.
  Sa-Nguanraksa Doonyapat et al. Asian Pacific journal of cancer prevention : APJCP 2019 20(8) 2385-2389
• Genetic testing in young women with breast cancer: results from a Web-based survey.
  Ruddy K J et al. Annals of oncology : official journal of the European Society for Medical Oncology 2010 Apr 21(4) 741-7

more